News

Durata Therapeutics (Durata) has acquired Vicuron Pharmaceuticals (Vicuron) from Pfizer (PFE). Durata is a newly formed biopharmaceutical company that was created to pursue late-stage clinical development of novel

Biovator and BASF have signed a collaboration agreement for final development of in-vitro test systems, capable of identifying the potential of chemical compounds to induce allergic reaction in

Seattle Genetics has entered into a collaboration agreement with GlaxoSmithKline (GSK) under which GSK will pay an upfront fee of $12m for rights to utilize Seattle Genetics’ antibody-drug

XenoTech has introduced its new product in the field of cryopreserved pooled human hepatocytes, CryostaX. The company said that CryostaX is the largest single-freeze pool of cryopreserved human

Neuralstem has reported that its Phase I trial to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) with its spinal cord stem cells has been approved by

Schott announced at the Pharma Symposium in Mainz, Germany that it has started mass production of its TopLyo pharmaceutical packaging for lyophilized (freezedried) drugs at its Muellheim, Germany

Mesa Laboratories has acquired the bottle cap torque testing business of Vibrac, a new Hampshire based company. Under this transaction, Vibrac is expected to sell the assets associated

Novartis has reported that its investigational vaccine, Menveo (Meningococcal Group A, C, W-135 and Y-CRM Conjugate Vaccine) has received a positive opinion from the Committee for Medicinal Products

Taro Pharmaceutical Industries (Taro) has initiated phase I clinical trials in Canada with T2007, the second in the company’s class of proprietary non-sedating barbiturate compounds to be approved